Tiziana seeks FDA orphan drug designation for intranasal foralumab in multiple system atrophy

Tiziana Life Sciences filed with the FDA for orphan drug designation for intranasal foralumab to treat multiple system atrophy; FDA typically reviews within 90 days, and a grant would confer incentives such as market exclusivity. The drug is in a Phase 2a open-label MSA trial at Brigham and Women’s Hospital under Mass General Brigham’s MyTrial program.